The drug is ponsegromab, a monoclonal antibody developed by Pfizer that blocks a hormone called GDF-15, which cancer tumors produce in excess to suppress appetite and drive dangerous weight loss. In a Phase 2 trial published in the New England Journal of Medicine in September 2024, patients receiving the highest dose of ponsegromab gained an average of 2.81 kilograms, roughly 6.6 pounds, over 12 weeks, along with measurable improvements in appetite, physical activity, and skeletal muscle mass. For the millions of cancer patients suffering from cachexia, a wasting syndrome with no FDA-approved treatment in the United States, this drug represents the first real pharmacological hope in more than 15 years of research.
This matters beyond oncology. For families navigating dementia care, appetite loss and unintentional weight loss are painfully familiar problems, and the biological pathways involved in cancer cachexia overlap with those seen in neurodegenerative disease. Understanding how ponsegromab works, what it achieved in clinical trials, and where it falls short offers a window into how medicine may eventually tackle wasting conditions more broadly. This article covers the science behind cancer cachexia, the trial results in detail, how ponsegromab compares to existing options like anamorelin and megestrol acetate, and what the path to approval looks like going forward.
Table of Contents
- How Does the Drug That Restores Appetite in Cancer Patients Actually Work?
- What the Phase 2 Trial Revealed About Ponsegromab’s Effectiveness
- Long-Term Results and What Happens When Treatment Continues
- How Ponsegromab Compares to Existing Appetite Drugs
- Why Cancer Cachexia Has Been So Difficult to Treat
- What This Means for Dementia Caregivers Watching a Loved One Lose Weight
- The Road to Approval and What Comes Next
- Conclusion
- Frequently Asked Questions
How Does the Drug That Restores Appetite in Cancer Patients Actually Work?
Cancer cachexia is not ordinary weight loss. It is a metabolic syndrome driven by the tumor itself, affecting up to 80 percent of patients with advanced cancer and directly contributing to 22 to 30 percent of all cancer deaths. The hallmark is involuntary loss of more than 5 percent of body weight over six months, often accompanied by a BMI below 20 and dangerously low muscle mass, a condition known as sarcopenia. Patients do not simply feel less hungry. Their bodies are being chemically instructed to waste away. Ponsegromab targets the specific chemical messenger behind much of this destruction: growth differentiation factor-15, or GDF-15. In healthy people, GDF-15 circulates at low levels and plays a modest role in regulating appetite and metabolism.
But many cancer tumors, particularly in the lungs, pancreas, and colon, produce GDF-15 in dramatically elevated quantities. The hormone travels to the brainstem, binds to a receptor called GFRAL, and effectively tells the brain to shut down hunger signals. Ponsegromab is a monoclonal antibody that intercepts GDF-15 before it reaches the brain, neutralizing the tumor’s ability to suppress appetite. Think of it as removing a chemical gag order the cancer has placed on the body’s desire to eat. What makes this mechanism especially compelling is its specificity. Previous attempts to treat cachexia used broad approaches, stimulating appetite with hormones or cannabinoids, but they rarely addressed the underlying metabolic disruption. Ponsegromab does not just make patients feel hungrier. By blocking GDF-15, it appears to allow the body to resume normal weight regulation, including the preservation and rebuilding of skeletal muscle, which is the tissue most critical to functional independence and survival.
What the Phase 2 Trial Revealed About Ponsegromab’s Effectiveness
The pivotal evidence comes from PROACC-1, a Phase 2, randomized, double-blind, placebo-controlled trial involving 187 patients with non-small cell lung cancer, pancreatic cancer, or colorectal cancer. All enrolled patients had elevated GDF-15 levels above 1,500 picograms per milliliter, confirming that the hormone was actively driving their wasting. Participants received subcutaneous injections of ponsegromab at doses of 100, 200, or 400 milligrams, or a placebo, once every four weeks for 12 weeks. The results were dose-dependent and striking. Patients on the 100-milligram dose gained an average of 1.22 kilograms, a 2.02 percent increase from baseline. The 200-milligram group gained 1.92 kilograms, or 3.48 percent.
And the 400-milligram group gained 2.81 kilograms, a 5.61 percent increase, which is a meaningful reversal in a population that is otherwise losing weight steadily. Beyond the scale, the highest-dose group showed improvements in appetite scores, cachexia-related symptoms, physical activity levels, and skeletal muscle mass, all measured using validated clinical instruments. However, a critical caveat: this was a Phase 2 trial, not the large-scale Phase 3 study needed for regulatory approval. The 187-patient sample, while encouraging, cannot answer questions about long-term survival benefit, effectiveness across all cancer types, or how the drug performs in patients with lower GDF-15 levels. The trial also enrolled relatively specific patients, and those with cachexia driven primarily by factors other than GDF-15 may not respond the same way. Promising Phase 2 results have failed to replicate in Phase 3 before, and researchers are appropriately cautious about declaring victory prematurely.
Long-Term Results and What Happens When Treatment Continues
One of the most common concerns with any weight-restoring drug is whether the gains last. Open-label extension data from the PROACC-1 trial provide early reassurance. Patients who continued on ponsegromab maintained their weight gain through 64 weeks of treatment, and suppression of GDF-15 levels persisted over the full follow-up period. This suggests the drug does not lose effectiveness over time, at least within the window studied so far. An especially telling finding came from the crossover group.
Patients who had been on placebo during the initial 12-week trial and then switched to ponsegromab during the extension phase also gained weight, but less than those who had been on the drug from the beginning. This pattern suggests that earlier intervention may produce better outcomes, a finding consistent with the broader understanding that cachexia becomes harder to reverse as muscle loss progresses. For caregivers, the implication is clear: if ponsegromab eventually reaches the market, the conversation about using it should happen early in a cancer diagnosis, not after significant wasting has already occurred. The safety profile over the extended treatment period remained favorable. During the initial trial, adverse events occurred in 70 percent of ponsegromab patients compared with 80 percent of those on placebo, an unusual finding where the treatment group actually fared better than the control group in terms of side effects. While longer and larger studies will be needed to confirm this safety record, the early data suggest that GDF-15 blockade does not come with the kind of trade-offs that have undermined previous cachexia therapies.
How Ponsegromab Compares to Existing Appetite Drugs
Ponsegromab is not entering an empty field, but the existing options are limited and largely unsatisfying. Megestrol acetate, a synthetic progestogen, is the most widely prescribed appetite stimulant for cancer patients in the United States. It works for some, with roughly 25 percent of patients reporting improved appetite, but only about 8 percent see meaningful weight gain. It also carries risks of blood clots, adrenal suppression, and fluid retention, and the weight gained is often fat rather than the muscle mass patients desperately need. Dronabinol, the synthetic cannabinoid sold as Marinol, offers another option. In a 139-patient trial, 38 percent of patients on dronabinol reported increased appetite compared with 8 percent on placebo.
But appetite improvement did not consistently translate into weight gain or improved function, and side effects including dizziness, mood changes, and confusion make it a poor fit for patients who are already cognitively vulnerable, an especially important consideration for anyone also managing dementia or age-related cognitive decline. Anamorelin, a ghrelin receptor agonist, comes closest to ponsegromab in terms of evidence. It was approved in Japan in January 2021 for cachexia associated with non-small cell lung cancer, gastric cancer, colorectal cancer, and pancreatic cancer. It has shown consistent ability to increase lean body mass in clinical trials. However, it has not received FDA approval in the United States, and its mechanism, mimicking the hunger hormone ghrelin, is fundamentally different from ponsegromab’s approach of blocking a tumor-derived appetite suppressant. The two drugs could theoretically complement each other, though no combination trials have been conducted.
Why Cancer Cachexia Has Been So Difficult to Treat
The reason no FDA-approved cachexia treatment exists in the United States after decades of research is not for lack of trying. The condition is deceptively complex. Cachexia involves simultaneous disruptions in appetite signaling, energy metabolism, protein synthesis, systemic inflammation, and hormonal regulation. Targeting any single pathway has historically produced modest benefits at best. Previous clinical trials have also struggled with a measurement problem. Weight gain alone does not prove a drug is working in a clinically meaningful way.
A patient can gain weight from fluid retention or fat accumulation without any improvement in muscle mass, physical function, or survival. Regulatory agencies, particularly the FDA, have pushed for trials that demonstrate not just weight change but functional improvement, things like the ability to walk further, perform daily tasks, or tolerate chemotherapy. This higher bar has caused several promising compounds to stall in development. Ponsegromab’s advantage may be that it addresses a specific, measurable biomarker. By selecting patients with elevated GDF-15 levels above 1,500 picograms per milliliter, the PROACC-1 trial effectively identified a population most likely to respond. This biomarker-driven approach is a departure from earlier cachexia trials that enrolled broadly and then struggled to show a treatment effect across heterogeneous patient groups. The limitation, of course, is that patients whose cachexia is not primarily GDF-15-driven may not benefit, and the prevalence of high GDF-15 across all cancer types is still being characterized.
What This Means for Dementia Caregivers Watching a Loved One Lose Weight
Appetite loss and wasting are not exclusive to cancer. People with moderate to advanced dementia frequently stop eating for reasons that overlap with cachexia biology, including neuroinflammation, elevated stress hormones, and disrupted hunger signaling. While ponsegromab is being developed strictly for cancer-associated cachexia, the science behind GDF-15 has broader implications. Elevated GDF-15 levels have been observed in aging populations and in people with chronic inflammatory conditions, raising the question of whether similar mechanisms contribute to the weight loss seen in neurodegenerative disease.
For families currently managing a loved one’s declining appetite, the immediate practical takeaway is not that ponsegromab will soon be available for dementia patients. It will not, at least not without years of additional research. The takeaway is that the medical establishment is finally treating involuntary weight loss as a treatable biological condition rather than an inevitable consequence of serious illness. That shift in thinking matters, because it drives funding, clinical attention, and eventually therapeutic options for wasting conditions beyond cancer.
The Road to Approval and What Comes Next
Pfizer planned to launch Phase 3 registration-enabling trials for ponsegromab in 2025, with a Phase 2b study in metastatic pancreatic cancer already underway to optimize dosing ahead of the pivotal trial. If Phase 3 results confirm what Phase 2 showed, ponsegromab could become the first FDA-approved treatment for cancer cachexia, a designation researchers have been chasing for well over a decade. As one investigator put it after the ESMO 2024 presentation, “We haven’t had anything like this in the field of cancer cachexia.” The broader significance extends beyond a single drug.
Ponsegromab’s success in Phase 2 has validated GDF-15 as a therapeutic target, which will likely spur development of competing drugs and combination approaches. For patients and caregivers, the most important development is not any one molecule but the growing recognition that wasting syndromes are not something to simply endure. They are medical conditions with biological drivers that can be identified, measured, and potentially reversed.
Conclusion
Ponsegromab represents the most significant advance in treating cancer-related appetite loss and wasting in at least 15 years. By targeting GDF-15, the hormone that tumors use to suppress hunger and drive weight loss, it achieved meaningful weight gain, improved muscle mass, and better physical function in a rigorous Phase 2 trial. Existing alternatives like megestrol acetate, dronabinol, and anamorelin offer partial relief for some patients, but none address the underlying tumor-driven biology the way ponsegromab does.
For families dealing with appetite loss in any serious illness, including dementia, the progress in cancer cachexia research signals a broader medical shift toward treating involuntary weight loss as a biological problem with biological solutions. Phase 3 trials will determine whether ponsegromab lives up to its early promise, and the coming years should clarify whether GDF-15 blockade has applications beyond oncology. In the meantime, anyone caring for a loved one experiencing unexplained weight loss should raise the topic with their medical team, because the field is moving, and treatment options are closer than they have ever been.
Frequently Asked Questions
What is cancer cachexia and how is it different from normal weight loss?
Cancer cachexia is a metabolic wasting syndrome driven by the tumor itself, not simply a result of eating less. It involves involuntary loss of more than 5 percent of body weight over six months, often with dangerous muscle wasting. Unlike dieting or reduced intake, cachexia cannot be fully reversed by eating more, because the tumor actively disrupts the body’s metabolism and appetite signaling.
Is ponsegromab available to patients now?
No. Ponsegromab is still in clinical development. The Phase 2 trial results were published in the New England Journal of Medicine in September 2024, and Pfizer planned to begin Phase 3 pivotal trials in 2025. There are currently no FDA-approved treatments for cancer cachexia in the United States.
Does ponsegromab work for all cancer patients with appetite loss?
Not necessarily. The PROACC-1 trial enrolled patients with elevated GDF-15 levels above 1,500 picograms per milliliter, specifically those with non-small cell lung cancer, pancreatic cancer, or colorectal cancer. Patients whose cachexia is driven by factors other than GDF-15, or who have different cancer types, may not respond the same way.
Could this drug help people with dementia who are losing weight?
There is no current evidence that ponsegromab works for dementia-related weight loss, and it is not being studied for that purpose. However, GDF-15 has been found at elevated levels in aging and inflammatory conditions, so the underlying science could eventually inform treatments for wasting in other diseases.
What appetite drugs are currently available for cancer patients?
The most commonly used options are megestrol acetate, which improves appetite in about 25 percent of patients, and dronabinol, a synthetic cannabinoid. Anamorelin is approved in Japan but not in the United States. None of these drugs specifically target the tumor-driven biology of cachexia the way ponsegromab does.
Were there serious side effects in the ponsegromab trial?
The drug was generally well-tolerated. Adverse events occurred in 70 percent of ponsegromab patients versus 80 percent of those on placebo, meaning the treatment group actually experienced fewer side effects than the control group. Long-term safety data through 64 weeks of the open-label extension also remained favorable, though larger Phase 3 trials will provide a more complete safety picture.
